Consent

Dear participant,

You are invited to participate in a study on intracranial hemorrhage in patients treated with extracorporeal life support by completing an online survey. The researchers are based at University Health Network (UHN) in Toronto, Canada.

There are wide variations in the reported incidence and prognosis of intracranial hemorrhage in the literature. This may in part be explained by significant variations between centers in terms of patient management in the absence of robust data or guidelines. The aim of this study is to describe the current practices surrounding the prevention, diagnosis, and management of intracranial hemorrhage in patients on extracorporeal membrane oxygenation across the world. We aim to obtain 200 answers.

Your answers will enhance our understanding of the topic, but you will not gain any direct benefit from your participation. Participation in this survey is completely voluntary. If you decide not to participate, there will not be any negative consequences. If you decide to participate, you may decide not to answer any specific question by skipping it. You may stop participating at any time by simply closing your browser. Your answers/ information will be collected and used only after clicking "done" at the end of the survey. Please note that once you submit the survey, it will not be possible to withdraw your data, as the survey is anonymous. Consent to participate in the study is implied upon completion and submission of the survey.

The survey is anonymous and as such will not be collecting information that will easily identify you, like your name or other unique identifiers. Although your Internet Protocol (IP) address can be tracked through the survey platform, the researchers will not be collecting this information. Additionally, there is no contract specific to the University Health Network that controls the disposition of the information. The unique web link that was provided in your invitation allows the researcher to track who responded but your answers will not be linked to your name, email or IP address.

To further protect your information, data stored on Survey Monkey (USA) servers is password-protected. Only the researchers named in this study will have access to the data as collected. Any future publications will include collective information. Your individual responses will not be shared with anyone outside of the research team.

Study data will be kept by the researchers at UHN for up to 5 years after the study is completed.

If you have any questions about the study or would like a copy of this consent letter, please contact Dr. Y.A. Cavayas, Research fellow at Interdepartmental Division of Critical Care Medicine, UHN - Toronto General Hospital: alex.cavayas@uhn.ca*

*Please note that communication via e-mail is not absolutely secure. Thus, please do not communicate personal sensitive information via e-mail.

The study has been reviewed by the UHN Research Ethics Board (contact number 416-581-7849).

Please print this page or write down the contact information in case you want to access this information once you complete the survey.

By submitting this form, you are indicating that you have read the description of the study and that you agree to the terms as described.

Thank you.

Best regards,

Yiorgos Alexandros Cavayas, MD Lorenzo del Sorbo, MD Eddy Fan, MD PhD

Interdepartmental Division of Critical Care Medicine, UHN-Toronto General Hospital, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada


ur center	
2. In what country is your ECMO center	
3. What is your background?	
Medicine: Anesthesia	Medicine: Emergency medicine
Medicine: Medical subspeciality	Perfusionnist
Medicine: Surgery	Nurse
4. For how long has your center had an E	CMO program?
<3 years	
3-6 years	
7-9 years	
>10 years	
5. How many <u>adult ECMO cases</u> did you բ	perform in the last 12 months in your center?
	Approximate number of cases
VV-ECMO	
VA-ECMO for cardiogenic shock	
cardiogenic shock	
cardiogenic shock ECPR TOTAL (all configurations	
cardiogenic shock ECPR TOTAL (all configurations	
cardiogenic shock ECPR TOTAL (all configurations	
cardiogenic shock ECPR TOTAL (all configurations	



Question 5



Int	Intracranial hemorrhage on ECMO					
Pe	Perceptions					
	embolism, the <u>risk of</u>	mpared anticoagulation alone to anticoagulation with fibrinolysis for acute pulmonary by intracranial bleeding in the anticoagulation alone group was 0.2%. (Chatterjee et would you compare the risk of intracranial bleeding in patients on ECMO?				
level of risk						
	VV-ECMO					
	VA-ECMO for cardiogenic shock					
	ECPR					



nts do you obtain i e ECMO initiation or in ECMO	maging of the brain (C the first 24 hours of	T/CTA/MRI) ? At any point during their ICU stay
e ECMO initiation or in		
e ECMO initiation or in		
	the first 24 hours of	At any point during their ICU stay
		k of major complications (such as cannul an ECMO patient to the radiology depart

Never (0%) 1-25% 26-50% 51-75% 76-100%


Intracranial hemorrhage on ECMO

Anticoagu	lation	manan	IAMANT
Allucuauu	ιαιιστι	IIIaiiau	CHICHL


Vocation of the content of the con	B. For a 70 kg male without any bleeding risk factor, No anticoagulant bolus	what bolus of heparin do you give during cannulation? 4000-6000 units
2000-3999 units Other anticoagulant used 10. For a 70 kg male without any bleeding risk factor, at what rate would you start your heparin infusion? no anticogulant infusion 1500-1999 units/h > 2000 units/h > 500-999 units/h Other anticoagulant used 1000-1499 units/h 11. What anticoagulation strategy do you adopt when there is no bleeding? Fixed infusion rate (i.e., no titration of anticoagulation) Anti-Xa target ACT target ACT target Heparin blood concentration target aPTT target Other (please specify) 12. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	_	
10. For a 70 kg male without any bleeding risk factor, at what rate would you start your heparin infusion? no anticogulant infusion 1500-1999 units/h >2000 units/h >2000 units/h Other anticoagulant used 1000-1499 units/h 11. What anticoagulation strategy do you adopt when there is no bleeding? Fixed infusion rate (i.e., no titration of anticoagulation)		
no anticogulant infusion	2000-3999 units	Other anticoagulant useu
<500 units/h >2000 units/h 500-999 units/h Other anticoagulant used 1000-1499 units/h 11. What anticoagulation strategy do you adopt when there is no bleeding? Fixed infusion rate (i.e., no titration of anticoagulation) Anti-Xa target ACT target Heparin blood concentration target aPTT target Other (please specify) 12. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	.0. For a 70 kg male without any bleeding risk facto	r, at what rate would you start your heparin infusion?
500-999 units/h 1000-1499 units/h 11. What anticoagulation strategy do you adopt when there is no bleeding? Fixed infusion rate (i.e., no titration of anticoagulation) ACT target ACT target APTT target Other (please specify) 12. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	no anticogulant infusion	1500-1999 units/h
11. What anticoagulation strategy do you adopt when there is no bleeding? Fixed infusion rate (i.e., no titration of anticoagulation) Arti-Xa target ACT target Heparin blood concentration target aPTT target Other (please specify) 12. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	<500 units/h	>2000 units/h
11. What anticoagulation strategy do you adopt when there is no bleeding? Fixed infusion rate (i.e., no titration of anticoagulation) Anti-Xa target ACT target APTT target Other (please specify) 12. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	500-999 units/h	Other anticoagulant used
Fixed infusion rate (i.e., no titration of anticoagulation) ACT target ACT target APTT target Other (please specify) 12. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	1000-1499 units/h	
Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant	aPTT target	Trepaint blood concentration target
usual target: What do you do with anticoagulation? Continue anticoagulation unchanged Reduce anticoagulant infusion and reduce target Stop anticoagulant		
Stop anticoagulant	usual target: What do you do with anticoagulation? Continue anticoagulation unchanged	cranial bleeding, and the clotting parameters are within
Stop anticoagulant and reverse effect (ex:protamine)	_	
	Stop anticoagulant and reverse effect (ex:protamine)	

13. If there is a confirmed or highly suspected intracranial bleeding, and the clotting parameters are within usual target: <u>Do you give antifibrinolytics?</u>	
No	
Yes	
Only if TEG/ROTEM suggestive of hyperfibrinolysis	

anofucion thus als	oldo	
ansfusion thresh	lolas	
14. What is your tra	nsfusion threshold for <u>packed Red Blood Cells?</u>	2
	No active bleeding	Intracranial bleeding
Hemoglobin		
15. What is your tra	nsfusion threshold for <u>Platelet concentrates?</u>	
	No active bleeding	Intracranial bleeding
Platelets		
16. What is your tra	nsfusion threshold for <u>Fresh Frozen Plasma?</u>	
	No active bleeding	Intracranial bleeding
INR		
17. What is your tra	nsfusion threshold for <u>Cryoprecipitates?</u>	
17. What is your tra	nsfusion threshold for <u>Cryoprecipitates?</u> No active bleeding	Intracranial bleeding
17. What is your tra		Intracranial bleeding
Fibrinogen	No active bleeding	
Fibrinogen		
Fibrinogen 18. Do you use TEG	No active bleeding	following blood products?
Fibrinogen	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEG	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets Fresh Frozen Plasma	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets Fresh Frozen Plasma	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets Fresh Frozen Plasma	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets Fresh Frozen Plasma	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets Fresh Frozen Plasma	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?
Fibrinogen 18. Do you use TEO Platets Fresh Frozen Plasma	No active bleeding G or ROTEM to guide the administration of the topic states and the states are also active bleeding.	following blood products?



Question 15



Question 16

```
1.0-1.4
1.5-1.9
>2.0
I give FFP, but not based on INR
I never give FFP in this situation
```

Question 17


```
= or < 1.0 g/L
1.1-1.5 g/L
1.6-2.0 g/L
>2.0 g/L
I never give Cryo in this situation
I give Cryo, but not based on fibrinogen levels
```

Question 18



acranial hemorrhage or	ECMO		
s exchange			
.9. In patients on VV-ECM	O, over what time period o	do you aim to correct t	he following parameters?
	PaCO2	рН	PaO2 and/or SpO2
Time			
20. What PaO2 do you tarç			
in patients on VV-	Low limit		High limit
ECMO?			
21. What SpO2 do you targ	uet?		
op o you	Low limit		High limit
in patients on VV-			
ECMO?			
22. What PaO2 do you tarç	get? (part 2)		
	Low limit		High limit
in patients on VA-ECMO for cardiogenic shock?			
in patients on ECPR?			

PaCO2



PH ✓ <1h 1-4 h 5-8 h 9-12 h 13-24 h >24 h I only target PaCO2




Question 20 Low limit

<40 mmHg (<5.3 kPa)</p>
40-50 mmHg (5.3-6.6 kPa)
50-59 mmHg (6.7-7.9 kPa)
60-79 mmHg (8.0-10.7 kPa)
= or > 80 mmHg (= or > 10.8 kPa)
I only target pulse oxymetry


High Limit

<80 mmHg (<10.7 kPa) 80-99 mmHg (10.7-13.2 kPa) 100-149 mmHg (13.3-19.9 kPa) 150-299 mmHg (20.0-39.9 kPa) = or > 300 mmHg (= or > 40.0 kPa) I only target pulse oxymetry


Question 21 Low limit



High limit



Question 22 Low limit



High limit

<80 mmHg (<10.7 kPa) 80-99 mmHg (10.7-13.2 kPa) 100-149 mmHg (13.3-19.9 kPa) 150-299 mmHg (20.0-39.9 kPa) = or > 300 mmHg (= or > 40.0 kPa) I only target SVO2 and/or lactates

Intracranial hemorrhage on ECMO

Outcomes	
23. What is the rate of ICH in your center? (please do	o not guess if you don't know)
Unknown	10-14%
0-4%	15%
5-9%	
24. In your experience, what is the rate of survivors in	ndependently living among patients with ICH?
Unknown	40-59%
0-19%	60-79%
20-39%	80-100%
	g and independently living, in a patient on ECMO who al brainstem function and a CT-scan showing multiple
0-19%	60-79%
20-39%	80-100%
40-59%	
	g and independently living, in a patient on ECMO who al brainstem function and a CT-Scan showing a single a, mass effect and a midline shift?
0-19%	60-79%
20-39%	80-100%
40-59%	

c_{1}	IDV	AIT.	c_{1}	1D1	/FY
. 71	ווחו	/11 1	. 71	ᇄ	/ IT Y

By clicking the "done" button below, you agree to the use of your information collected in this survey for research purposes

DONE